SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-004289
Filing Date
2023-01-23
Accepted
2023-01-23 08:30:13
Documents
3
Period of Report
2023-01-23

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea172042-6k_nlspharma.htm 6-K 11205
2 PRESS RELEASE TITLED: "NLS PHARMACEUTICS ANNOUNCES NEW IN-VITRO DATA HIGHLIGHTIN ea172042ex99-1_nlspharma.htm EX-99.1 16905
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5536
  Complete submission text file 0001213900-23-004289.txt   36871
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 23542596
SIC: 2834 Pharmaceutical Preparations